Study of a PRMT5 inhibitor for MTAP-deleted solid tumors
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new drug called BAY 3713372 in people with solid tumors that have a specific genetic change called MTAP deletion. The drug targets a process inside cells that may help stop tumor growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- Your tumor must have a specific genetic change called MTAP deletion.
- You must have at least one tumor that can be measured on scans.
- You must be able to do most daily activities on your own (ECOG 0 or 1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called PEP08 for people with advanced solid tumors that have a specific genetic change (MTAP deletion). It might be an option if standard treatments no longer work or cause too many side effects.
This trial tests an experimental drug called BMS-986504, given alone or with other drugs, for people with advanced solid tumors that have a specific genetic change called a homozygous MTAP deletion. It may be an option if standard treatments are no longer working or aren't available.
This trial tests a new experimental drug (HSK41959) for people with advanced solid tumors that have a specific genetic change (MTAP deletion). The goal is to see if the drug is safe and effective for tumors that no longer respond to standard treatments.
This trial tests an investigational drug called AZD3470, which blocks a protein called PRMT5, in people whose tumors lack a gene called MTAP. The goal is to see if the drug can shrink tumors or slow their growth.
This study tests a new drug, BMS-986504, to see how it is processed and removed from the body in people with certain advanced solid tumors. It is for patients whose cancer has a specific genetic change (MTAP deletion) and who have no other good treatment options.
This Phase 1 trial studies MRTX1719, a new medicine, in solid tumors that have a missing MTAP gene (MTAP deletion). It aims to find the safest dose and check how the drug affects the tumor.
Hear when a new MTAP-deleted Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.